Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Christopher J Sweeney, M.B.,B.S.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA238020 (SWEENEY, CHRISTOPHER J) May 1, 2020 - Apr 30, 2025
    NIH/NCI
    Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer
    Role: Principal Investigator
  2. R01CA208254 (SWEENEY, CHRISTOPHER J) Aug 15, 2016 - Jul 31, 2019
    NIH/NCI
    Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer
    Role: Principal Investigator
  3. R03CA156048 (SWEENEY, CHRISTOPHER J) Dec 1, 2010 - Nov 30, 2012
    NIH/NCI
    Evaluating a parthenolide analogue as a new bladder and kidney cancer therapy
    Role: Principal Investigator
  4. U54CA156732 (VISWANATH, KASISOMAYAJULA) Sep 27, 2010 - Aug 31, 2021
    NIH/NCI
    2/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
    Role: Co-Principal Investigator
  5. M01RR000750 (BRATER, D CRAIG) Dec 1, 1976 - Nov 30, 2009
    NIH/NCRR
    General Clinical Research Center
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Font-Tello A, Kesten N, Xie Y, Taing L, Varešlija D, Young LS, Hamid AA, Van Allen EM, Sweeney CJ, Gjini E, Lako A, Hodi FS, Bellmunt J, Brown M, Cejas P, Long HW. FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nat Protoc. 2020 Jun 26. PMID: 32591768.
    Citations:    
  2. Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Berry D, Clarke N, Collette L, D'Amico A, Lourenco RA, Dignam J, Eisenberger M, James N, Fizazi K, Gillessen S, Loriot Y, Mottet N, Parulekar W, Sandler H, Spratt DE, Sydes MR, Tombal B, Williams S, Sweeney CJ. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 Jun 18; JCO1903114. PMID: 32552276.
    Citations:    
  3. Hearn JWD, Sweeney CJ, Almassi N, Reichard CA, Reddy CA, Li H, Hobbs B, Jarrard DF, Chen YH, Dreicer R, Garcia JA, Carducci MA, DiPaola RS, Sharifi N. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncol. 2020 Feb 13; e196496. PMID: 32053149.
    Citations:    
  4. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 Apr; 77(4):508-547. PMID: 32001144.
    Citations:    
  5. Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020 03; 31(3):412-421. PMID: 32067683.
    Citations:    
  6. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2019 12; 30(12):e3. PMID: 32041688.
    Citations:    
  7. Bernard B, Burnett C, Sweeney CJ, Rider JR, Sridhar SS. Impact of age at diagnosis of de novo metastatic prostate cancer on survival. Cancer. 2020 Mar 01; 126(5):986-993. PMID: 31769876.
    Citations:    
  8. Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, Mucci LA. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 Mar 01; 26(5):1086-1093. PMID: 31754047.
    Citations:    
  9. Fankhauser CD, Sweeney CJ, Connors JM. Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer. Eur Urol. 2020 Mar; 77(3):388-390. PMID: 31718823.
    Citations:    
  10. Davis ID, Stockler MR, Sweeney CJ. Enzalutamide in Metastatic Prostate Cancer. Reply. N Engl J Med. 2019 10 10; 381(15):1494-1495. PMID: 31597033.
    Citations:    
  11. Sweeney CJ, Beltran H. The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data. Eur Urol. 2019 12; 76(6):729-731. PMID: 31590937.
    Citations:    
  12. VanderWeele DJ, Antonarakis ES, Carducci MA, Dreicer R, Fizazi K, Gillessen S, Higano CS, Morgans AK, Petrylak DP, Sweeney CJ, Hussain M. Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. J Clin Oncol. 2019 11 10; 37(32):2961-2967. PMID: 31498754.
    Citations:    
  13. Santos JMO, Moreira-Pais A, Neto T, Peixoto da Silva S, Oliveira PA, Ferreira R, Mendes J, Bastos MMSM, Lopes C, Casaca F, Silva S, Sweeney C, Medeiros R, Gil da Costa RM. Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16-transgenic mice. Drug Dev Res. 2019 09; 80(6):824-830. PMID: 31301186.
    Citations:    
  14. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019 07 11; 381(2):121-131. PMID: 31157964.
    Citations:    
  15. Morel KL, Ormsby RJ, Klebe S, Sweeney CJ, Sykes PJ. DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo. Radiat Res. 2019 08; 192(2):231-239. PMID: 31095445.
    Citations:    
  16. Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 06; 114:107-116. PMID: 31082669.
    Citations:    
  17. Stoneham S, Murray M, Thomas B, Williamson M, Sweeney C, Frazier L. AYA testis cancer: The unmet challenge. Pediatr Blood Cancer. 2019 08; 66(8):e27796. PMID: 31066223.
    Citations:    
  18. Prast-Nielsen S, Tobin AM, Adamzik K, Powles A, Hugerth LW, Sweeney C, Kirby B, Engstrand L, Fry L. Investigation of the skin microbiome: swabs vs. biopsies. Br J Dermatol. 2019 09; 181(3):572-579. PMID: 30693476.
    Citations:    Fields:    
  19. Sweeney CJ, De Abreu Lourenco R, Hamid AA, Buyse M. What Does Metastasis-Free Survival Actually Mean? J Clin Oncol. 2019 07 01; 37(19):1679-1680. PMID: 31050909.
    Citations:    
  20. Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. Eur J Cancer. 2019 06; 114:128-136. PMID: 31060925.
    Citations:    
  21. McKay R, Mills H, Werner L, Choudhury A, Choueiri T, Jacobus S, Pace A, Polacek L, Pomerantz M, Prisby J, Sweeney C, Walsh M, Taplin ME. Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. J Med Internet Res. 2019 05 02; 21(5):e12044. PMID: 31045501.
    Citations:    
  22. McGregor BA, Miller RE, O'Donnell E, Albiges LK, Sweeney CJ, Markt SC. Body Mass Index and Outcomes in Germ-Cell Tumors. Clin Genitourin Cancer. 2019 08; 17(4):283-290. PMID: 31129146.
    Citations:    
  23. AlDubayan SH, Pyle LC, Gamulin M, Kulis T, Moore ND, Taylor-Weiner A, Hamid AA, Reardon B, Wubbenhorst B, Godse R, Vaughn DJ, Jacobs LA, Meien S, Grgic M, Kastelan Z, Markt SC, Damrauer SM, Rader DJ, Kember RL, Loud JT, Kanetsky PA, Greene MH, Sweeney CJ, Kubisch C, Nathanson KL, Van Allen EM, Stewart DR, Lessel D. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncol. 2019 Apr 01; 5(4):514-522. PMID: 30676620.
    Citations:    Fields:    
  24. Sweeney CJ. Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer. Eur Urol Focus. 2019 03; 5(2):111-113. PMID: 30898552.
    Citations:    
  25. Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019 04; 20(4):518-530. PMID: 30857956.
    Citations:    
  26. Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, van Andel G, Clarke NW, Hulshof MC, James ND, Parker CC, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Verhagen PC, Tierney JF. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 2019 07; 76(1):115-124. PMID: 30826218.
    Citations:    
  27. Vapiwala N, Hofman MS, Murphy DG, Williams S, Sweeney C. Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. J Clin Oncol. 2019 04 01; 37(10):765-769. PMID: 30794477.
    Citations:    
  28. Xie W, Halabi S, Tierney JF, Sydes MR, Collette L, Dignam JJ, Buyse M, Sweeney CJ, Regan MM. A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz002. PMID: 31360890.
    Citations:    
  29. Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, Kantoff PW, Taplin ME, Sweeney CJ. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019 09; 22(3):420-427. PMID: 30643173.
    Citations:    Fields:    
  30. Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, Sweeney CJ. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2019 07; 76(1):89-97. PMID: 30553611.
    Citations:    
  31. Withington J, Cole AP, Meyer CP, Seisen T, Schmid M, Lipsitz SR, Sweeney CJ, Dasgupta P, Trinh QD. Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany. BJU Int. 2019 03; 123(3):385-387. PMID: 30536825.
    Citations:    Fields:    
  32. McKay RR, Werner L, Jacobus SJ, Jones A, Mostaghel EA, Marck BT, Choudhury AD, Pomerantz MM, Sweeney CJ, Slovin SF, Morris MJ, Kantoff PW, Taplin ME. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2019 02 15; 125(4):524-532. PMID: 30427533.
    Citations:    Fields:    
  33. Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ. Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 03; 28(3):584-590. PMID: 30420441.
    Citations:    Fields:    
  34. Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ. Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clin Genitourin Cancer. 2019 Feb; 17(1):32-37. PMID: 30348512.
    Citations:    Fields:    
  35. Hamid AA, Gray KP, Huang Y, Bowden M, Pomerantz M, Loda M, Sweeney CJ. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. Eur Urol Oncol. 2019 09; 2(5):475-482. PMID: 31411988.
    Citations:    
  36. Tosco L, Briganti A, D'amico AV, Eastham J, Eisenberger M, Gleave M, Haustermans K, Logothetis CJ, Saad F, Sweeney C, Taplin ME, Fizazi K. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. Eur Urol. 2019 01; 75(1):44-60. PMID: 30286948.
    Citations:    Fields:    
  37. Howard SA, Rosenthal MH, Qin L, Matalon SA, Bernard BD, Beard CJ, Sweeney CJ. Quantifying Decreased Radiation Exposure From Modern CT Scan Technology and Surveillance Programs of Germ Cell Tumors. Am J Clin Oncol. 2018 10; 41(10):949-952. PMID: 28654572.
    Citations:    Fields:    
  38. Hamid AA, Markt SC, Vicier C, McDermott K, Richardson P, Ho VT, Sweeney CJ. Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clin Genitourin Cancer. 2019 Feb; 17(1):58-64.e1. PMID: 30309761.
    Citations:    Fields:    
  39. Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 02; 75(2):285-293. PMID: 30119985.
    Citations:    Fields:    
  40. Sussman G, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, Grattan C, Hollis K, Hunter S, Knulst A, Lacour JP, Lynde C, Marsland A, McBride D, Maurer M, Nakonechna A, Ortiz de Frutos J, Reynolds M, Sweeney C, Tian H, Weller K, Wolin D, Balp MM. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE-CSU. Allergy. 2018 Aug; 73(8):1724-1734. PMID: 29460968.
    Citations:    
  41. Sweeney CJ. Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next? Eur Urol. 2018 10; 74(4):420-421. PMID: 30007817.
    Citations:    Fields:    Translation:Humans
  42. Reynolds PS, Fisher BJ, McCarter J, Sweeney C, Martin EJ, Middleton P, Ellenberg M, Fowler E, Brophy DF, Fowler AA, Spiess BD, Natarajan R. Interventional vitamin C: A strategy for attenuation of coagulopathy and inflammation in a swine multiple injuries model. J Trauma Acute Care Surg. 2018 07; 85(1S Suppl 2):S57-S67. PMID: 29538225.
    Citations: 2     Fields:    
  43. Morel KL, Ormsby RJ, Solly EL, Tran LNK, Sweeney CJ, Klebe S, Cordes N, Sykes PJ. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clin Exp Metastasis. 2018 10; 35(7):649-661. PMID: 29936575.
    Citations:    Fields:    
  44. Choudhury AD, Gray KP, Supko JG, Harshman LC, Taplin ME, Pace AF, Farina M, Zukotynski KA, Bernard B, Kantoff PW, Pomerantz M, Sweeney C. A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07. PMID: 29882250.
    Citations:    
  45. Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Invest. 2018 07 02; 128(7):2979-2995. PMID: 29863497.
    Citations:    Fields:    
  46. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Reply to J.J. Tao et al. J Clin Oncol. 2018 08 10; 36(23):2451. PMID: 29856693.
    Citations:    Fields:    
  47. Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Rydzewska LH, Sweeney CJ, Spears MR, Sydes MR, Tierney JF. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol. 2018 05 01; 29(5):1249-1257. PMID: 29788164.
    Citations:    Fields:    
  48. Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 05; 131(5):517-523. PMID: 29555248.
    Citations:    Fields:    
  49. Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol. 2018 04 10; 36(11):1088-1095. PMID: 29522362.
    Citations: 1     Fields:    
  50. Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol. 2018 06; 73(6):847-855. PMID: 29475737.
    Citations: 2     Fields:    
  51. Deraska PV, O'Leary C, Reavis HD, Labe S, Dinh TK, Lazaro JB, Sweeney C, D'Andrea AD, Kozono D. NF-?B inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. Cell Death Discov. 2018 Dec; 4:10. PMID: 29531807.
    Citations:    
  52. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 04 10; 36(11):1080-1087. PMID: 29384722.
    Citations: 8     Fields: